Document is current
Any future updates will be listed below
-
Authors
Mattsson-Carlgren, Niklas https://orcid.org/0000-0002-8885-7724
Karlsson, Linda https://orcid.org/0000-0002-0630-772X
Tang, Weizhong
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Bateman, Randall J https://orcid.org/0000-0002-7729-1702
Schindler, Suzanne E
Barthelemy, Nicolas
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Stomrud, Erik
Janelidze, Shorena
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
-
Funding
Funding for this research was provided by:
Swedish Research Council (2025-02319)
Swedish Alzheimer Foundation (AF-1011799)
EC | European Research Council (ADG-101096455)
Alzheimer's Association (ZEN24-1069572)
Alzheimer's Association (ALZSI-26-1523522)
Knut and Alice Wallenberg Foundation (2022-0231)
Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University
Swedish Brain Foundation (FO2025-0055)
Parkinson foundation of Sweden (1412/22)
Familjen Rönnströms Stiftelse
WASP and DDLS Joint call for research projects (WASP/DDLS22-066)
Michael J Fox Foundation (MJFF-025507)
Cure Alzheimer's Fund
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
Skåne University Hospital Foundation (2020-O000028)
Global Research and Imaging Platform
Regionalt Forskningsstöd
Swedish federal government under the ALF agreement (2022-Projekt0107)
- License Information
-
More Information
Article History
Received: 18 June 2025
Revised: 7 November 2025
Accepted: 13 November 2025
First Online: 1 December 2025
Disclosure and competing interests statement
: NMC has received consulting/speaker fees from BioArctic, Biogen, Eli Lilly, Merck, Novo Nordisk, and Owkin. KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. SP has acquired research support (for the institution) from ki elements/ADDF and Avid. In the past 2 years, he has received consultancy/speaker fees from Bioartic, Biogen, Esai, Eli Lilly, and Roche. SES has served on scientific advisory boards on biomarker testing and clinical treatment pathways for Eisai and Novo Nordisk, and has received speaking fees from Eli Lilly. OH is an employee of Lund University and Eli Lilly.
